PTX V3
Alternative Names: PTX-V3; PTX_V3Latest Information Update: 12 Jul 2022
At a glance
- Originator pHion Therapeutics
- Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Prostate cancer